We recently published a list of 20 Mid-Cap Stocks Insiders Were Buying in Q1 2025. In this article, we are going to take a ...

Shares of Charles River Laboratories International Inc. CRL rose 1.73% to $106.05 Thursday, on what proved to be an ...

Charles River (CRL) saw its shares surge in the last session with trading volume being higher than average. The latest trend ...

Charles River Laboratories International Inc. closed 60.67% short of its 52-week high of $254.15, which the company achieved ...

We recently published a list of Traders Heavily Sold Down These 10 Stocks on Thursday. In this article, we are going to take ...

Charles River Labs faces a 60% loss due to reduced R&D spending, FDA's phase-out of animal testing, and increased competition ...

Baird analyst Eric Coldwell raised the firm’s price target on Charles River (CRL) to $118 from $101 and keeps a Neutral rating on the shares.

On Thursday, shares in Charles River Laboratories, a leading contract research organizations that has stirred controversy over its use of non-human primates, plunged 28 percent after the FDA issued ...

Portuguese biotech FairJourney Biologics has acquired South San Francisco antibody R&D facility from Charles River Labs, ...

Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2025 financial results on Wednesday, May 7th, before the market opens. A conference call has been scheduled to ...

BofA analyst Michael Ryskin lowered the firm’s price target on Charles River (CRL) to $150 from $185 and keeps a Neutral rating on the shares.